Regado BioSciences, Inc. News Headlines

RGDO 
$1.19
*  
0.01
0.83%
Get RGDO Alerts
*Delayed - data as of Mar. 3, 2015  -  Find a broker to begin trading RGDO now
Exchange: NASDAQ
Industry: Health Care
Community Rating:
View:    RGDO Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Arena Pharmaceuticals Doses for Cardiovascular Study - Analyst Blog
1/16/2015 2:20:00 PM - Investopedia


Arena Pharmaceuticals Doses for Cardiovascular Study - Analyst Blog
1/16/2015 2:20:00 PM - Zacks.com


Regado Biosciences to Merge with Tobira Therapeutics - Analyst Blog
1/15/2015 2:30:00 PM - Investopedia


Regado Biosciences Long Thesis Remains Intact
1/15/2015 9:55:00 AM - Seeking Alpha


Regado Biosciences And Tobira Therapeutics To Merge - Quick Facts
1/14/2015 8:19:00 AM - RTT News


Emergent BioSolutions Provides Preliminary 2014 Results - Analyst Blog
1/12/2015 6:30:00 PM - Zacks.com


Argos Therapeutics Falls on Disappointing Phase IIb HIV Data - Analyst Blog
1/12/2015 4:20:00 PM - Zacks.com


Emergent BioSolutions Provides Preliminary 2014 Results - Analyst Blog
1/12/2015 6:30:00 AM - Investopedia


Argos Therapeutics Falls on Disappointing Phase IIb HIV Data - Analyst Blog
1/12/2015 4:20:00 AM - Investopedia


Biogen Reveals Positive Data from Acute Optic Neuritis Study - Analyst Blog
1/9/2015 5:35:00 PM - Zacks.com


Biogen Reveals Positive Data from Acute Optic Neuritis Study - Analyst Blog
1/9/2015 5:35:00 AM - Investopedia


Eli Lilly Maintains '14 View, Growth to Resume in 2015 - Analyst Blog
1/8/2015 12:29:00 PM - Investopedia


Eli Lilly Maintains '14 View, Growth to Resume in 2015 - Analyst Blog
1/8/2015 12:29:00 PM - Zacks.com


Alkermes Gains on Positive Depression Drug Study Data - Analyst Blog
1/7/2015 5:10:00 PM - Zacks.com


Alkermes Gains on Positive Depression Drug Study Data - Analyst Blog
1/7/2015 5:10:00 AM - Investopedia


Minerva Neurosciences' MIN-301 Positive in Primate Study - Analyst Blog
1/6/2015 7:20:00 PM - Zacks.com


Immunomedics' Breast Cancer Drug Gets Fast Track Status - Analyst Blog
1/6/2015 1:50:00 PM - Investopedia


Immunomedics' Breast Cancer Drug Gets Fast Track Status - Analyst Blog
1/6/2015 1:50:00 PM - Zacks.com


Minerva Neurosciences' MIN-301 Positive in Primate Study - Analyst Blog
1/6/2015 7:20:00 AM - Investopedia


Biotech Weekly: Top Value Biotech Picks For 2015
1/5/2015 9:01:00 AM - Seeking Alpha


Synthetic Biologics Commences Phase Ib Study on SYN-004 - Analyst Blog
12/31/2014 2:40:00 PM - Investopedia


Synthetic Biologics Commences Phase Ib Study on SYN-004 - Analyst Blog
12/31/2014 2:40:00 PM - Zacks.com


Vertex Pharmaceuticals' Kalydeco Label Expanded in the U.S. - Analyst Blog
12/30/2014 4:30:00 PM - Zacks.com


Ignyta's Lead Oncology Candidate Gets Orphan Drug Status - Analyst Blog
12/30/2014 3:20:00 PM - Zacks.com


Vertex Pharmaceuticals' Kalydeco Label Expanded in the U.S. - Analyst Blog
12/30/2014 4:30:00 AM - Investopedia